文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术后使用TYTOCARE™家庭远程监测设备优化术后结局

TYTOCARE™ home telemonitoring device after radical cystectomy to optimise postoperative outcomes.
PubMed 文献 · BJU Int · 2024-12-26

这项前瞻性单中心研究评估了根治性膀胱切除术后早期家庭远程监测TYTOCARE™方案的作用,共纳入16例干预组和88例对照组患者。结果显示干预组住院时间更短(11 vs 14天;P=0.04)、医疗并发症更少(2/16 vs 21/88;P=0.02),30天内再入院为0例,对照组为20.4%。作者认为该方案似乎可行且患者依从性高。

要点

  • TYTOCARE™组住院时间11天 vs 对照组14天(P=0.04),医疗并发症2/16 vs 21/88(P=0.02)。
  • TYTOCARE™组30天内再入院0例,对照组20.4%。
  • 患者VAS满意度均值86.4分,医护人员92.3分,TSQ均值4.3分,全部患者表示会使用并推荐该设备。

核心结论

  • TYTOCARE™远程监测方案似乎可行且患者及照护者依从性高,并减少了住院时间、医疗并发症和出院后30天内再入院。

研究设计与样本

  • 前瞻性单中心研究,纳入2021年3月至2023年8月在本机构接受根治性膀胱切除术、年龄<80岁且可上网的患者,出院后使用TYTOCARE™远程医疗系统进行家庭监测。
  • TYTOCARE™组16例,对照组88例(同一研究期间接受根治性膀胱切除术但未参加术后远程监测方案),比较人口学、围手术期数据、术后并发症及出院后30天内再入院。

主要发现

  • TYTOCARE™组住院时间11天 vs 对照组14天(P=0.04)。
  • TYTOCARE™组医疗并发症2/16 vs 对照组21/88(P=0.02)。
  • TYTOCARE™组30天内再入院0例,对照组20.4%。
  • 患者VAS满意度均值86.4分,医护人员92.3分;TSQ均值4.3分;全部TYTOCARE™患者表示会使用并推荐该设备;2例出现轻微技术问题,均易于解决。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the role of the TYTOCARE™ telemedicine programme for home telemonitoring during the early postoperative period following radical cystectomy (RC) in a prospective single-centre study. MATERIALS AND METHODS: The study included patients aged <80 years with internet access who underwent RC at our institution between March 2021 and August 2023. Upon discharge, patients were monitored at home using the TYTOCARE™ telemedicine system. Daily, patients completed a symptom questionnaire and recorded heart rate, body temperature, intestinal sounds, and urine output, and wound/ostomy evaluations via photos. Weekly televisits via the TYTOCARETM platform and app were scheduled, with additional controls as needed. After 30 days, patients assessed their satisfaction using a visual analogue scale (VAS; 0-100) and a Telemedicine Satisfaction Questionnaire (TSQ; 1-5) and any technical issues were documented. A control group of patients, who underwent RC in the same study period but who did not take part in a postoperative telemonitoring programme, was chosen for comparison, with analysis of demographics, peri-operative data, postoperative complications and hospital readmissions within 30 days after discharge. RESULTS: A total of 16 patients were included in the TYTOCARETM group, and 88 in the control group. The mean VAS satisfaction scores were 86.4 (patients) and 92.3 (healthcare providers). The mean TSQ score was 4.3, indicating high satisfaction. All TYTOCARETM patients reported they would use and recommend the device. Two patients encountered minor technical issues, which were easily resolved. The TYTOCARETM group had a shorter hospital stay (11 vs 14 days; P = 0.04) and fewer medical complications ( 2/16 vs 21/88; P = 0.02). No TYTOCARETM patients were readmitted within 30 days, compared to 20.4% in the control group. CONCLUSION: The TYTOCARETM telemonitoring programme seems to be feasible and highly adhered to by patients and caregivers, with reductions in length of hospital stay, medical complications and hospital readmissions within the first 30 days post-discharge.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Amparore D, De Cillis S, Colombo M, et al. TYTOCARE™ home telemonitoring device after radical cystectomy to optimise postoperative outcomes. BJU Int. 2024. PMID: 39725555. doi:10.1111/bju.16637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。